{
    "clinical_study": {
        "@rank": "26736", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, retrospective, observational study will evaluate the therapeutic\n      effectiveness of a strategy of induction with Fuzeon (enfuvirtide) within an optimized\n      regimen of antiretroviral drugs in patients with HIV-1 infection in routine clinical\n      practice."
        }, 
        "brief_title": "An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection", 
        "completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  HIV-1+ infection\n\n          -  Patients with a viral load > 50 copies/ml who have received induction treatment with\n             Fuzeon in combination with antiretroviral treatment\n\n          -  Na\u00efve for Fuzeon at initiation of induction treatment\n\n          -  Antiretroviral treatment of at least 12 months duration\n\n        Exclusion Criteria:\n\n          -  Patients who did not receive Fuzeon treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with HIV-1 infection having received induction therapy with Fuzeon and\n        antiretroviral drugs"
            }
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902615", 
            "org_study_id": "ML25313"
        }, 
        "intervention_browse": {
            "mesh_term": "Enfuvirtide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08901"
                }
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Multicenter, Observational, Retrospective Study to Assess the Therapeutic Effectiveness of a Strategy of Induction With Enfuvirtide Within an Optimized Regimen of Antiretroviral Drugs (ARV) in Patients Infected With HIV-1 in Routine Clinical Practice", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Response rate: Proportion of patients with reduction of viral load to < 50 copies/ml", 
            "safety_issue": "No", 
            "time_frame": "approximately 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of treatment with Fuzeon", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }, 
            {
                "measure": "Time to undetectability, defined as time from initiation of treatment to first observation of viral load < 50 copies/ml", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }, 
            {
                "measure": "Treatment regimen: Antiretroviral drugs used", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}